Stockscreener 앱 받기
0.4833
1.57%
-0.0077
전일 마감가:
$0.491
열려 있는:
$0.481
하루 거래량:
190.22K
Relative Volume:
0.50
시가총액:
$19.96M
수익:
$9.57M
순이익/손실:
$-43.11M
주가수익비율:
-0.2894
EPS:
-1.67
순현금흐름:
$-49.54M
1주 성능:
-1.49%
1개월 성능:
-13.08%
6개월 성능:
-35.65%
1년 성능:
-64.46%
1일 변동 폭
$0.4801
$0.5198
1주일 범위
$0.4716
$0.5198
52주 변동 폭
$0.4112
$5.95
스프루스 바이오 Stock (SPRB) Company Profile
명칭
Spruce Biosciences Inc
전화
(415) 655-4168
주소
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
SPRB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| SPRB | 0.4833 | 19.96M | 9.57M | -43.11M | -49.54M | -1.67 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
스프루스 바이오 Stock (SPRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | The Benchmark Company | Speculative Buy |
| 2021-11-16 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | 개시 | H.C. Wainwright | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-11-03 | 개시 | Cowen | Outperform |
| 2020-11-03 | 개시 | Credit Suisse | Outperform |
| 2020-11-03 | 개시 | RBC Capital Mkts | Outperform |
| 2020-11-03 | 개시 | SVB Leerink | Outperform |
모두보기
스프루스 바이오 주식(SPRB)의 최신 뉴스
Spruce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Layoff Tracker: Gilead Sciences Will Lay Off 104 Employees at California HQ - BioSpace
ARMISTICE CAPITAL, LLC Acquires New Stake in Spruce Biosciences Inc - GuruFocus.com
Spruce Biosciences Inc (SPRB) Quarterly 10-Q Report - Quartz
Spruce Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Scholz Advisers Slash German Growth Forecast for Next Year - Yahoo Finance
Spruce Biosciences' SWOT analysis: tildacerfont's fate hangs on Q4 trial results - Investing.com Canada
EchoStar Q3 Earnings Lag Estimates on Lower Revenues, Stock Down 13% - Yahoo Finance
Spruce Biosciences Faces Nasdaq Delisting Threat: Can a Reverse Stock Split Save Its Market Presence? - TipRanks
Spruce Biosciences Reports Q3 2024 Earnings and Updates - Yahoo Finance
Should Value Investors Buy Silvercorp Metals (SVM) Stock? - Yahoo Finance
Spruce Biosciences, Inc. (SPRB) Reports Q3 Loss, Lags Revenue Estimates - MSN
US opens probe into 1.4 million Honda vehicles over engine issues - Yahoo Canada Finance
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - BioSpace
Why Cambium (CMBM) International Revenue Trends Deserve Your Attention - Yahoo Finance
Spruce Biosciences Trims Losses, Eyes Critical Clinical Data in December | SPRB Stock News - StockTitan
Don't Race Out To Buy Enbridge Inc. (TSE:ENB) Just Because It's Going Ex-Dividend - Yahoo Finance
Caribou Biosciences (NASDAQ:CRBU) vs. Sutro Biopharma (NASDAQ:STRO) Financial Analysis - Defense World
Brokerages Set Element Solutions Inc (NYSE:ESI) Target Price at $31.00 - Defense World
Vitro Diagnostics (OTCMKTS:VODG) and Tectonic Therapeutic (NASDAQ:TECX) Critical Comparison - Defense World
Analysts Set Spruce Biosciences, Inc. (NASDAQ:SPRB) Price Target at $5.00 - Defense World
Spruce Biosciences faces Nasdaq delisting notice - Investing.com India
Spruce Biosciences faces Nasdaq delisting notice By Investing.com - Investing.com South Africa
Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference - Business Wire
Global Adrenogenital Syndrome Treatment Market to Reach USD 22.08 Billion in 2033, Driven by New The - PharmiWeb.com
Congenital Adrenal Hyperplasia Clinical Trials 2024: FDA Approvals, Companies, Medication, Treatment Market, Therapies, ROA and MOA by DelveInsight | Becton, Dickinson and Company, Cook Medical, MORE - Barchart
Floyd Mayweather Jr buying $402M Black Spruce portfolio - Yahoo Finance
Congenital Adrenal Hyperplasia (CAH) Therapeutic Market 2024 - openPR
Ambev S.A. (NYSE:ABEV) Given Average Rating of “Hold” by Brokerages - Defense World
Daily Progress: Spruce Biosciences Inc (SPRB) Drop -5.56, Closing at 0.43 - The Dwinnex
The Significance of Moving Averages in Spruce Biosciences Inc Inc. (SPRB) Price Performance - The InvestChronicle
A closer look at Spruce Biosciences Inc (SPRB)’s stock price trends - US Post News
North Carolina town that produces quartz needed for tech products is devastated by Helene - Yahoo Finance
Spruce Biosciences' SWOT analysis: tildacerfont trials key for CAH stock - Investing.com
Spruce Biosciences' SWOT analysis: tildacerfont trials key for CAH stock By Investing.com - Investing.com UK
Neurocrine Biosciences's Crinecerfont is Set to Transform the Congenital Adrenal Hyperplasia Treatment Market | DelveInsight - PR Newswire
Recent Insider Activity Suggests Potential Gains for Spruce Biosciences Inc (SPRB) - Knox Daily
Spruce Biosciences Inc (SPRB) expanding its growth trajectory ahead - SETE News
Spruce Biosciences Inc [SPRB] stock for 350,951 USD was sold by Novo Holdings A/S - Knox Daily
Spruce Biosciences Inc’s results are impressive - US Post News
Financial Fitness Check: Examining Spruce Biosciences Inc (SPRB)’s Key Ratios - The Dwinnex
Checking in on Spruce Biosciences Inc (SPRB) after recent insiders movement - Knox Daily
Life Time Group Holdings Inc (LTH) gets rating Initiated from Craig Hallum - Knox Daily
Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Potential Price Increase for Spruce Biosciences Inc (SPRB) After Recent Insider Activity - Knox Daily
SPRBSpruce Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
An Inquiry Has Been Launched Into Whether Spruce Biosciences Inc. Violated Securities Regulations And Stockholders Are Encouraged To Assist - StockTitan
Spruce Biosciences Inc (SPRB) Becoming More Attractive for Investors - Knox Daily
SPRB (Spruce Biosciences) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com
SPRB (Spruce Biosciences) Dividends per Share : $0.00 (TTM As of Jun. 2024) - GuruFocus.com
Spruce Power Holding Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.17 profit in 2Q 2023) - Yahoo Finance
스프루스 바이오 (SPRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
스프루스 바이오 주식 (SPRB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Novo Holdings A/S | 10% Owner |
Mar 18 '24 |
Sale |
0.77 |
842,020 |
647,008 |
3,968,000 |
| Novo Holdings A/S | 10% Owner |
Mar 19 '24 |
Sale |
0.76 |
593,000 |
447,715 |
3,375,000 |
| Novo Holdings A/S | 10% Owner |
Mar 20 '24 |
Sale |
0.73 |
359,979 |
264,081 |
3,015,021 |
| Novo Holdings A/S | 10% Owner |
Mar 14 '24 |
Sale |
0.89 |
1,912,316 |
1,698,902 |
4,810,020 |
| Charlton Ralph William III | Chief Medical Officer |
Dec 15 '23 |
Option Exercise |
0.00 |
31,750 |
0 |
56,992 |
| Gharib Samir M. | President & CFO |
Dec 15 '23 |
Option Exercise |
0.00 |
112,250 |
0 |
204,403 |
| Szwarcberg Javier B. | Chief Executive Officer |
Dec 15 '23 |
Option Exercise |
0.00 |
111,000 |
0 |
145,705 |
1.89%
2.08%
자본화:
|
볼륨(24시간):